FDA approves Opdivo® (nivolumab) for patients with previously treated SCLC
Bristol-Myers Squibb announced that Opdivo (nivolumab) received approval from the FDA as the first and only Immuno-Oncology treatment option for patients with metastatic small cell lung cancer whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. August 17, 2018